A Phase 2 interventional study of BHV-7000 and BHV-7000 in Focal Epilepsy, sponsored by Biohaven Therapeutics Ltd.. Enrolling by invitation at 283 sites in 27 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Biohaven Therapeutics Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 4th largest by planned enrollment of the 86 interventional ones that give a count, is one of 6 that started in 2024, is one of 23 in phase 2, reaches primary completion later than 3 of the 22 other live ones, and was the 91st registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 660 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Biohaven Therapeutics Ltd. has 3 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A study to determine if BHV- 7000 is safe and tolerable in adults with refractory focal onset epilepsy
Key Inclusion Criteria:
Key Exclusion Criteria:
Drug: BHV-7000
Drug: BHV-7000
Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs.
Time frame: Up to 104 weeks
Number of Subjects with Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000. This objective will be measured by assessing the number of unique subjects with grade 3 or 4 laboratory abnormalities.
Time frame: Up to 104 weeks
Showing the first 100 of 283 sites across 27 countries. Choose a country and city above to see the rest.
Started Jul 2024 (actual). Primary completion is estimated for Dec 2026, 29 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opakalim
Biohaven Therapeutics Ltd.